From the outside, Washington appears even more volatile than usual right now. As a result, regulated industries are under extraordinary external pressure, driving shifts in priorities among their leadership. Inside government agencies, however, what appears to be volatility is actually a deliberate effort to recalibrate without abandoning the mission.
The gap between outside perceptions and internal processes is driving companies to misread risk. After serving in senior communications roles at both the Department of Homeland Security (DHS) and the Food and Drug Administration (FDA), and working in both Republican and Democratic administrations, I learned that when scrutiny intensifies, the worst mistake is overreacting to noise.
At DHS, I worked alongside teams responsible for protecting the nation’s critical infrastructure, including the healthcare and public health sector. Through the Cybersecurity and Infrastructure Security Agency, DHS partners with hospitals, pharmaceutical manufacturers, medical device companies, and public health agencies to strengthen resilience against cyber and physical threats. Those partnerships continue regardless of political cycles or headlines, because healthcare delivery and supply chain integrity are matters of national security.
FDA is now operating in a similarly visible environment. The intersection of administration priorities, industry advocacy, and agency process is more public than it has been in years. But visibility is not the same as instability. When scrutiny rises, internal discipline typically increases. Decision pathways become more deliberate. The process tightens. Informal clarity may narrow, but statutory obligations and Center-level expertise continue to drive outcomes. That perspective is shaping how I am advising clients right now.
Stability and Continuity Lives in Statute and Centers
Across government, authority matters more than rhetoric. At DHS, infrastructure security and resilience efforts continue under authority established by law, even when there is leadership change. The same principle applies at FDA where authorities, user fee commitments, and Center structures remain intact.
Within FDA’s Center for Drug, Evaluation and Research, rare disease programs and expedited pathways continue to operate within established frameworks. In the Center for Devices and Radiological Health, modernization efforts around breakthrough technologies and AI-enabled devices reflect sustained priorities rather than reactive policy swings. Leadership may change. The scientific and regulatory integrity does not. In moments of noise, the Centers remain the most reliable indicator of how decisions will ultimately land.
Visibility is Not Policy
Agencies under scrutiny often communicate more frequently. That does not mean policy has shifted at the same pace. Meaningful change still emerges through guidance, rulemaking, advisory committee processes, and formal review decisions. High-profile remarks or social posts are signals, not endpoints.
For companies operating in regulated sectors, that distinction matters. Increased visibility from leadership or political stakeholders can create the impression that regulatory standards are shifting quickly. In practice, the evidence-based frameworks and statutory requirements that govern FDA decisions rarely move that fast.
Transition Increases Caution, Not Chaos
Leadership transitions are demanding for career staff. When pressure rises, institutional risk management intensifies. Even amid high-profile initiatives, FDA must still rely on the strengths of each Center to meet its mission. CDER continues advancing complex applications. CDRH continues implementing oversight frameworks. The work of review divisions does not pause because the narrative shifts. What can feel unpredictable externally is often internal calibration.
The Communications Function Shifts in This Environment
In periods like this, the most valuable role of communications leadership is not amplification. It is interpretation. Not every announcement requires immediate recalibration. Not every signal warrants a response. The differentiator is the ability to distinguish meaningful policy movement from directional signaling and translate that distinction into disciplined internal action. Agencies under scrutiny can appear volatile from the outside. From the inside, they are usually working to preserve continuity while adapting to new expectations. In moments of scrutiny, disciplined judgment is not caution. It is strategy.
For companies operating in highly regulated sectors, the practical takeaway is clear. Moments of heightened scrutiny in Washington rarely change the underlying regulatory foundations overnight, but they do create pressure to interpret signals quickly and accurately. The leaders who navigate these periods most effectively focus less on headlines and more on where statutory authority, user fee commitments, and Center-level priorities are moving.
That discipline allows companies to stay aligned with how agencies really make decisions rather than reacting to every shift in the public narrative. In moments like this, understanding how government works internally becomes a strategic advantage.
